Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
221.99B
Market cap221.99B
Price-Earnings ratio
25.31
Price-Earnings ratio25.31
Dividend yield
2.44%
Dividend yield2.44%
Average volume
2.78M
Average volume2.78M
High today
$411.00
High today$411.00
Low today
$404.05
Low today$404.05
Open price
$405.00
Open price$405.00
Volume
142.17K
Volume142.17K
52 Week high
$447.03
52 Week high$447.03
52 Week low
$288.00
52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $410.62. The company's market cap stands at 221.99B, with a P/E ratio of 25.31 and a dividend yield of 2.44%.

During the trading session on 2026-10-09, Amgen(AMGN) shares reached a daily high of $411.00 and a low of $404.05. At a current price of $410.62, the stock is +1.6% higher than the low and still -0.1% under the high.

Trading volume for Amgen(AMGN) stock has reached 142.17K, versus its average volume of 2.78M.

The stock's 52-week range extends from a low of $288.00 to a high of $447.03.

The stock's 52-week range extends from a low of $288.00 to a high of $447.03.

AMGN News

TipRanks 1h
Amgen price target raised to $470 from $430 at UBS

UBS raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma an...

Simply Wall St 11h
Amgen In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued

Amgen (AMGN) is back in focus after fresh attention on its obesity drug candidate MariTide, now in late-stage Phase III testing, and new precision medicine part...

Amgen In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued
TipRanks 21h
Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen lines up a head-to-head diabetes trial that could reshape the GLP-1 landscape. The...

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Zacks 1d
Stock Market News for Oct 8, 2026

Wall Street ended higher on Wednesday as market participants assessed the Federal Reserve’s rate outlook and economic data. The Nasdaq Composite, the Dow and th...

Stock Market News for Oct 8, 2026
Simply Wall St 2d
How Investors Are Reacting To Amgen Earnings Beat

Amgen recently reported quarterly revenue and earnings per share that were above consensus expectations and joined a $30 million Series A round for Arboretum Li...

How Investors Are Reacting To Amgen Earnings Beat
Zacks 2d
Amgen Advances While Market Declines: Some Information for Investors

In the latest trading session, Amgen (AMGN Quick QuoteAMGN - Free Report) closed at $413.08, marking a +2.6% move from the previous day. The stock's perfo...

Amgen Advances While Market Declines: Some Information for Investors
TipRanks 2d
Early notable gainers among liquid option names on October 7th

Notable gainers among liquid option names this morning include Gilead (GILD) $148.10 +3.88, NetApp (NTAP) $234.28 +5.83, Amgen (AMGN) $412.67 +10.07, Marathon P...

Benzinga 2d
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera - Benzinga

...

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera - Benzinga
TipRanks 3d
Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race

Amgen Inc (AMGN) announced an update on their ongoing clinical study. The study, titled “A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascend...

Zacks 3d
Amgen Inc. Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN Quick QuoteAMGN - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some o...

Amgen Inc. Is a Trending Stock: Facts to Know Before Betting on It

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.